Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Bergur V. Stefánsson"'
Autor:
Niels Jongs, Anna Maria Langkilde, John J.V. McMurray, Robert D. Toto, Fan Fan Hou, Ricardo Correa-Rotter, Bergur V. Stefánsson, Priya Vart, Hiddo J.L. Heerspink, David Wheeler, José Luis Górriz, Glenn M. Chertow, C. David Sjöström, Peter Rossing
Publikováno v:
Journal of the American Society of Nephrology, 32(8), 2352-2361. AMER SOC NEPHROLOGY
Chertow, G M, Vart, P, Jongs, N, Toto, R D, Gorriz, J L, Hou, F F, McMurray, J J V, Correa-Rotter, R, Rossing, P, Sjöström, C D, Stefánsson, B V, Langkilde, A M, Wheeler, D C & Heerspink, H J L 2021, ' Effects of dapagliflozin in stage 4 chronic kidney disease ', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2352-2361 . https://doi.org/10.1681/ASN.2021020167
J Am Soc Nephrol
Chertow, G M, Vart, P, Jongs, N, Toto, R D, Gorriz, J L, Hou, F F, McMurray, J J V, Correa-Rotter, R, Rossing, P, Sjöström, C D, Stefánsson, B V, Langkilde, A M, Wheeler, D C & Heerspink, H J L 2021, ' Effects of dapagliflozin in stage 4 chronic kidney disease ', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2352-2361 . https://doi.org/10.1681/ASN.2021020167
J Am Soc Nephrol
BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and
Autor:
Niels, Jongs, Glenn M, Chertow, Tom, Greene, John J V, McMurray, Anna Maria, Langkilde, Ricardo, Correa-Rotter, Naoki, Kashihara, Peter, Rossing, C David, Sjöström, Bergur V, Stefánsson, Robert D, Toto, David C, Wheeler, Hiddo J L, Heerspink
Publikováno v:
Journal of the American Society of Nephrology. AMER SOC NEPHROLOGY
Dapagliflozin reduces kidney failure risk in patients with CKD but can result in a reversible acute reduction in eGFR upon treatment initiation. Determinants of this eGFR reduction and its associations with efficacy and safety outcomes are unknown.Th
Autor:
Niels Jongs, Bergur V. Stefánsson, Ricardo Correa-Rotter, Robert D. Toto, John J.V. McMurray, Tom Greene, Dapa-Ckd Trial Committees, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink, David C. Wheeler, Glenn M. Chertow, Investigators, Peter Rossing
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 755-766. ELSEVIER SCIENCE INC
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and norm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89091bdd4249d265893bbdc171c8e7e
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272
Autor:
David C. Wheeler, Hiddo J.L. Heerspink, Fan Fan Hou, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Robert D. Toto, Ricardo Correa-Rotter, Peter Rossing, Niels Jong, David C Sjostrom, Bergur V. Stefánsson
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Reductions in albuminuria are consistently associated with a subsequent lower risk of kidney failure. The sodium glucose co-transporter 2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes.
Autor:
Hiddo J.L. Heerspink, David Cherney, Douwe Postmus, Bergur V. Stefánsson, Glenn M. Chertow, Jamie P. Dwyer, Tom Greene, Mikhail Kosiborod, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Glenn Chertow, Fan Fan Hou, John McMurray, Robert Toto, Bergur Stefansson, L.E. Maffei, P. Raffaele, S.E. Solis, C.A. Arias, D. Aizenberg, C. Luquez, C. Zaidman, N. Cluigt, M. Mayer, A. Alvarisqueta, A. Wassermann, R. Maldonado, J. Bittar, M. Maurich, L.E. Gaite, N. Garcia, L. Sivak, P.O. Ramallo, J.C. Santos, R. Garcia Duran, J.A. Oddino, A. Maranon, L.N. Maia, D.D. Avila, E.J.G. Barros, M.H. Vidotti, D. Panarotto, I.D.L. Noronha, L.A.A. Turatti, L. Deboni, M.E. Canziani, M.C. Riella, M.R. Bacci, R.P. Paschoalin, R.J. Franco, J.C. Goldani, E. St-Amour, A.W. Steele, R. Goldenberg, S. Pandeya, H. Bajaj, D. Cherney, S.M. Kaiser, J.R. Conway, S.S. Chow, G. Bailey, J. Lafrance, J. Winterstein, S. Cournoyer, D. Gaudet, F. Madore, R.L. Houlden, A. Dowell, M. Langlois, N. Muirhead, H. Khandwala, A. Levin, F. Hou, Y. Xue, L. Zuo, C. Hao, Z. Ni, C. Xing, N. Chen, Y. Dong, R. Zhou, X. Xiao, Y. Zou, C. Wang, B. Liu, Q. Chen, M. Lin, Q. Luo, D. Zhang, J. Wang, M. Chen, X. Wang, A. Zhong, J. Dong, C. Zhu, T. Yan, P. Luo, Y. Ren, P. Pai, D. Li, R. Zhang, J. Zhang, M. Xu, Y. Zhuang, Y. Kong, X. Yao, X. Peng, F.I. Persson, T.K. Hansen, R. Borg, U. Pedersen Bjergaard, D. Hansen, M. Hornum, H. Haller, G. Klausmann, D. Tschope, T. Kruger, P. Gross, C. Hugo, N. Obermuller, L. Rose, P. Mertens, H. Zeller-Stefan, A. Fritsche, L. Renders, J. Muller, K. Budde, B. Schroppel, I. Wittmann, P. Voros, M. Dudas, G.A. Tabak, R. Kirschner, A. Letoha, I. Balku, Z. Hermanyi, G. Zakar, I. Mezei, G.G. Nagy, J. Lippai, A. Nemeth, D. Khullar, P.K. Gowdaiah, E. Fernando Mervin, V.A. Rao, D. Dewan, K. Goplani, V.S.K. Maddi, M.S. Vyawahare, R.K. Pulichikkat, R. Pandey, S.K. Sonkar, V.K. Gupta, S. Agarwal, A.J. Asirvatham, A. Ignatius, S. Chaubey, S. Melemadathil, H. Alva, Y. Kadam, H. Shimizu, A. Sueyoshi, H. Takeoka, Y. Abe, T. Imai, Y. Onishi, Y. Fujita, Y. Tokita, M. Oura, Y. Makita, A. Idogaki, R. Koyama, H. Kikuchi, N. Kashihara, T. Hayashi, Y. Ando, T. Tanaka, M. Shimizu, S. Hidaka, T. Gohda, K. Tamura, M. Abe, Y. Kamijo, T. Imasawa, Y. Takahashi, M. Nakayama, M. Tomita, F. Hirano, Y. Fukushima, A. Kiyosue, S. Kurioka, E. Imai, K. Kitagawa, M. Waki, J. Wada, K. Uehara, H. Iwatani, K. Ota, S. Shibazaki, K. Katayama, I. Narita, M. Iinuma, S. Matsueda, S. Sasaki, A. Yokochi, T. Tsukamoto, T. Yoshimura, S. Kang, S. Lee, C.S. Lim, H. Chin, K.W. Joo, S.Y. Han, T.I. Chang, S. Park, H. Park, C.W. Park, B.G. Han, D.R. Cha, S.A. Yoon, W. Kim, S.W. Kim, D. Ryu, R. Correa Rotter, S.S. Irizar Santana, G. Hernandez Llamas, R. Valdez Ortiz, N.C. Secchi Nicolas, G. Gonzalez Galvez, J.R. Lazcano Soto, T. Bochicchio Riccardelli, E.A. Bayram Llamas, D.R. Ramos Ibarra, M.G.S. Melo, J.G. Gonzalez Gonzalez, J.H. Sanchez Mijangos, M. Madero Robalo, A. Garcia Castillo, H.A. Manrique, J.C. Farfan, R. Vargas, A. Valdivia, A. Dextre, E. Escudero, J.R. Calderon Ticona, L. Gonzales, J. Villena, L. Leon, G. Molina, A. Saavedra, E. Garrido, H. Arbanil, S. Vargas Marquez, J. Rodriguez, R. Isidto, A.J. Villaflor, M.A. Gumba, L. Tirador, R.S. Comia, R.A. Sy, M.L.V.V. Guanzon, G. Aquitania, N.C. De Asis, A.A. Silva, C.M. Romero, M.E. Lim, R.A. Danguilan, M. Nowicki, H. Rudzki, K. Landa, I. Kucharczyk-Bauman, B. Gogola-Migdal, M. Golski, A. Olech-Cudzik, T. Stompor, T. Szczepanik, B. Miklaszewicz, R. Sciborski, M. Kuzniewski, K. Ciechanowski, D. Wronska, W. Klatko, S. Mazur, G. Popenda, M. Myslicki, L.Z. Bolieva, S. Berns, A. Galyavich, T. Abissova, I. Karpova, D. Platonov, N. Koziolova, L. Kvitkova, R. Nilk, T. Medina, A. Rebrov, M. Rossovskaya, I. Sinitsina, E. Vishneva, N. Zagidullin, T. Novikova, N. Krasnopeeva, O. Magnitskaya, N. Antropenko, M. Batiushin, V. Escudero Quesada, C. Barrios Barrea, E. Espinel Garauz, J.M. Cruzado Garrit, C. Morales Portillo, J.L. Gorriz Teruel, S. Cigarran Guldris, M. Praga Terente, N.R. Robles Perez-Monteoliva, F.J. Tinahones Madueno, A. Soto Gonzalez, C. Diaz Rodriguez, H. Furuland, A. Saeed, K. Dreja, J. Spaak, A. Bruchfeld, M. Kolesnyk, O. Levchenko, N. Pyvovarova, V. Stus, V. Doretskyy, N. Korobova, O. Horoshko, I. Katerenchuk, Y.M. Mostovoy, M. Orynchak, O. Legun, I. Dudar, O. Bilchenko, S. Andreychyn, A. Levchenko, L. Zub, N. Tereshchenko, I. Topchii, T. Ostapenko, S. Bezuglova, M. Kopytsya, O. Turenko, P. Mark, J. Barratt, S. Bhandari, D. Fraser, P. Kalra, S.P. Kon, K. Mccafferty, A. Mikhail, O.P. Alvarado, R. Anderson, N.S. Andrawis, A. Arif, S.A. Benjamin, G. Bueso, R.S. Busch, K.W. Carr, P. Crawford, N. Daboul, G.M. De La Calle, B. Delgado, J. Earl, M.A. El-Shahawy, R.J. Graf, G. Greenwood, A. Guevara, E.M. Wendland, R.K. Mayfield, M. Montero, D.J. Morin, P. Narayan, V. Numrungroad, A.C. Reddy, R. Reddy, M.B. Samson, R. Trejo, M.B. Butcher, J.K. Wise, L.R. Zemel, M. Raikhel, D. Weinstein, P. Hernandez, A. Wynne, B.V. Khan, G.A. Sterba, A. Jamal, D. Ross, S.F. Rovner, A. Tan, F. Ovalle, R.J. Patel, J. Talano, D.R. Patel, A. Burgner, N. Aslam, M. Elliott, S. Goral, A. Jovanovich, J.A. Manley, K. Umanath, D. Waguespack, D. Weiner, M. Yu, L. Schneider, D. Jalal, T. Le, N. Nguyen, H. Nguyen, D. Nguyen, V. Nguyen, T. Do, P. Chu, D. Ta, N. Tran, B. Pham, Marc A. Pfeffer, Stuart Pocock, Karl Swedberg, Jean L. Rouleau, Nishi Chaturvedi, Peter Ivanovich, Andrew S. Levey, Heidi Christ-Schmidt, Claes Held, Christina Christersson, Johannes Mann, Christoph Varenhorst
Publikováno v:
Heerspink, H J L & DAPA-CKD Trial Committees and Investigators 2022, ' A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function ', Kidney International, vol. 101, no. 1, pp. 174-184 . https://doi.org/10.1016/j.kint.2021.09.005
Kidney International, 101(1), 174-184. ELSEVIER SCIENCE INC
Kidney International, 101(1), 174-184. ELSEVIER SCIENCE INC
This pre-specified analysis of DAPA-CKD assessed the impact of sodium-glucose cotransporter 2 inhibition on abrupt declines in kidney function in high-risk patients based on having chronic kidney disease (CKD) and substantial albuminuria. DAPA-CKD wa
Autor:
Peter J. Greasley, Klaas Hoogenberg, Daniel Reyner, Daniël H. van Raalte, Gozewijn D. Laverman, Annemarie B van der Aart-van der Beek, Qiang Li, David Z.I. Cherney, Gian Luca Di Tanna, Hiddo J.L. Heerspink, Bergur V. Stefánsson
Publikováno v:
Diabetes, Obesity and Metabolism, 23(8), 1961-1967. Wiley-Blackwell
Diabetes, Obesity and Metabolism, 23(8), 1961-1967. Wiley
van der Aart-van der Beek, A B, Cherney, D, Laverman, G D, Stefansson, B, van Raalte, D H, Hoogenberg, K, Reyner, D, Li, Q, di Tanna, G L, Greasley, P J & Heerspink, H J L 2021, ' Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials ', Diabetes, Obesity and Metabolism, vol. 23, no. 8, pp. 1961-1967 . https://doi.org/10.1111/dom.14411
Diabetes, Obesity & Metabolism
Diabetes, Obesity and Metabolism, 23(8), 1961-1967. Wiley
van der Aart-van der Beek, A B, Cherney, D, Laverman, G D, Stefansson, B, van Raalte, D H, Hoogenberg, K, Reyner, D, Li, Q, di Tanna, G L, Greasley, P J & Heerspink, H J L 2021, ' Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials ', Diabetes, Obesity and Metabolism, vol. 23, no. 8, pp. 1961-1967 . https://doi.org/10.1111/dom.14411
Diabetes, Obesity & Metabolism
High protein intake may increase intraglomerular pressure through dilation of the afferent arteriole. Sodium-glucose cotransporter-2 (SGLT2) inhibitors may reduce intraglomerular pressure through activation of tubuloglomerular feedback. Given these o
Autor:
David C. Wheeler, Peter Rossing, Bergur V. Stefánsson, Hiddo J.L. Heerspink, Carol A. Pollock, Daniel Reyner, Anna Maria Langkilde, C. David Sjöström
Publikováno v:
Pollock, C, Stefánsson, B, Reyner, D, Rossing, P, Sjöström, C D, Wheeler, D C, Langkilde, A M & Heerspink, H J L 2019, ' Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT) : a randomised, double-blind, placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 6, pp. 429-441 . https://doi.org/10.1016/S2213-8587(19)30086-5
Lancet Diabetes & Endocrinology, 7(6), 429-441. ELSEVIER SCIENCE INC
Lancet Diabetes & Endocrinology, 7(6), 429-441. ELSEVIER SCIENCE INC
Background: In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. We assessed the albuminuria-lowering effect of the sodium-glucose co-tran
Autor:
Claire C J Dekkers, David C. Wheeler, C. David Sjöström, Hiddo J.L. Heerspink, Valerie A. Cain, Bergur V. Stefánsson
Publikováno v:
Nephrology Dialysis Transplantation, 33(11), 2005-2011. Oxford University Press
Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation
Background. The sodium-glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin: creatinine ratio (UACR) in patients with type 2 diabetes. The efficacy and safety of this
Autor:
David C. Wheeler, Peter J. Greasley, C. David Sjöström, Hiddo J.L. Heerspink, Bergur V. Stefánsson, Peter Sartipy, Ricardo Correa-Rotter, Valerie A. Cain
Publikováno v:
Data in Brief
Data in Brief, Vol 37, Iss, Pp 107237-(2021)
Data in brief, 37:107237. Elsevier
Data in Brief, Vol 37, Iss, Pp 107237-(2021)
Data in brief, 37:107237. Elsevier
Dapagliflozin is a highly selective sodium-glucose cotransporter 2 inhibitor associated with stabilization of estimated glomerular filtration rate (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood pressure, body weight, and albuminuri
Autor:
José Luis Górriz, Rey Isidto, Bergur V. Stefánsson, Roberto Pecoits-Filho, Fan Fan Hou, Naoki Kashihara, David Z.I. Cherney, Magnus Lindberg, Tom Greene, John J.V. McMurray, Hans Furuland, C. David Sjöström, David C. Wheeler, István Wittmann, Robert D. Toto, Hiddo J.L. Heerspink, Peter Rossing, Dinesh Khullar, Kausik Umanath, M. M. Batiushin, Frederik Persson, Oleksandr Bilchenko, Patrick B. Mark, Walter Douthat, Hermann Haller, Michał Nowicki, Anna Maria Langkilde, Jamie P. Dwyer, Elizabeth Escudero, Ricardo Correa-Rotter, Pham van Bui, Shin Wook Kang, Glenn M. Chertow
Publikováno v:
Wheeler, D C, Stefansson, B V, Batiushin, M, Bilchenko, O, Cherney, D Z I, Chertow, G M, Douthat, W, Dwyer, J P, Escudero, E, Pecoits-Filho, R, Furuland, H, Górriz, J L, Greene, T, Haller, H, Hou, F F, Kang, S W, Isidto, R, Khullar, D, Mark, P B, McMurray, J J V, Kashihara, N, Nowicki, M, Persson, F, Correa-Rotter, R, Rossing, P, Toto, R D, Umanath, K, Van Bui, P, Wittmann, I, Lindberg, M, Sjöström, C D, Langkilde, A M & Heerspink, H J L 2020, ' The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial : baseline characteristics ', Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association, vol. 35, no. 10, pp. 1700-1711 . https://doi.org/10.1093/ndt/gfaa234
Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation, 35(10), 1700-1711. Oxford University Press
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation, 35(10), 1700-1711. Oxford University Press
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64da7bd72f832e16b03efa545ce968f9
https://eprints.gla.ac.uk/222782/1/222782.pdf
https://eprints.gla.ac.uk/222782/1/222782.pdf